中国科学院机构知识库网格
Chinese Academy of Sciences Institutional Repositories Grid
首页 机构 成果 学者
  
  1. CAS IR Grid
  2. 合肥物质科学研究院
  3. 中国科学院合肥物质科学研究院
EGFR exon 20 insertion mutations in non-small cell lung cancer

文献类型：期刊论文

作者Wang, Fenfang3,4; Li, Chenghui1,5; Wu, Qihuan6; Lu, Hongyang1,2
刊名TRANSLATIONAL CANCER RESEARCH
出版日期2020-04-01
卷号9
关键词EGFR exon 20 insertion mutations non-small cell lung cancer (NSCLC) EGFR-TKIs structural features clinical features treatment prognosis
ISSN号2218-676X
DOI10.21037/tcr.2020.03.10
通讯作者Lu, Hongyang(luhy@zjcc.org.cn)
英文摘要Mutations in the epidermal growth factor receptor (EGFR) gene are the most common targetable genomic drivers of non-small cell lung cancer (NSCLC). 90% of the EGFR mutations comprise of EGFR exon 19 deletion and exon 21 L858R mutation, while EGFR exon 20 insertion (EGFR Ex20Ins) is the third most common type of EGFR mutation. Currently, studies on EGFR Ex20Ins are relatively scarce and limited. The frequency of EGFR Ex20Ins mutations in NSCLC was 1-10%. Patients harboring EGFR Ex20Ins exhibited similar clinical characteristics except for poorer prognosis as compared to patients with sensitizing mutations in EGFR. Conventional TKIs have poor efficacy in a majority of EGFR Ex20Ins subtypes. Chemotherapy remains the preferred treatment for advanced NSCLC patients harboring EGFR Ex20Ins. However, some novel inhibitors are considered as putative candidates. This review focuses on the structural and biochemical features, clinical characteristics, treatments, and prognosis of EGFR Ex20Ins in NSCLC.
WOS关键词GROWTH-FACTOR-RECEPTOR ; NSCLC PATIENTS ; INHIBITOR ; EFFICACY ; HETEROGENEITY ; OSIMERTINIB ; AFATINIB ; OUTCOMES ; GENE ; RARE
资助项目Zhejiang Province Medical Science Fund[2019ZH019] ; CSCO-Qilu Cancer Research Foundation[Y-Q201802-008] ; 1022 Talent Training Program of Zhejiang Cancer Hospital
WOS研究方向Oncology
语种英语
WOS记录号WOS:000530914200083
出版者AME PUBL CO
资助机构Zhejiang Province Medical Science Fund ; CSCO-Qilu Cancer Research Foundation ; 1022 Talent Training Program of Zhejiang Cancer Hospital
源URL[http://ir.hfcas.ac.cn:8080/handle/334002/103239]  
专题中国科学院合肥物质科学研究院
通讯作者Lu, Hongyang
作者单位1.Chinese Acad Sci, Zhejiang Canc Hosp, Canc Hosp,Univ Chinese Acad Sci, Dept Thorac Med Oncol,Inst Canc Res & Basic Med S, Hangzhou 310022, Peoples R China
2.Chinese Acad Sci, Zhejiang Canc Hosp, Canc Hosp,Univ Chinese Acad Sci,Inst Canc Res & B, Zhejiang Key Lab Diag & Treatment Technol Thorac, Hangzhou 310022, Peoples R China
3.Xiangshan First Peoples Hosp, Dept Med Oncol, Xiangshan 315700, Peoples R China
4.Wenzhou Med Univ, Grad Sch, Wenzhou 325035, Peoples R China
5.Zhejiang Chinese Med Univ, Clin Med Coll 2, Hangzhou 310053, Peoples R China
6.Xiangshan First Peoples Hosp, Dept Med Emergency, Xiangshan 315700, Peoples R China
推荐引用方式
GB/T 7714		 Wang, Fenfang,Li, Chenghui,Wu, Qihuan,et al. EGFR exon 20 insertion mutations in non-small cell lung cancer[J]. TRANSLATIONAL CANCER RESEARCH,2020,9.
APA Wang, Fenfang,Li, Chenghui,Wu, Qihuan,&Lu, Hongyang.(2020).EGFR exon 20 insertion mutations in non-small cell lung cancer.TRANSLATIONAL CANCER RESEARCH,9.
MLA Wang, Fenfang,et al."EGFR exon 20 insertion mutations in non-small cell lung cancer".TRANSLATIONAL CANCER RESEARCH 9(2020).

入库方式： OAI收割

来源：合肥物质科学研究院

浏览0
下载0
收藏0
其他版本

除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。